The latest market intelligence, insights and interviews covering the cell and gene therapy industry's most pressing challenges, from translation to automation, manufacturing to market access, viral vectors to bioreactors.

The A-Z of Advanced Therapies

Phacilitate's picks of the A to Z of advanced therapies

Phacilitate Working Group Report: Standardising Tubing Connectivity

A summary report of the working group for sterile tubing connectivity meeting to discuss guidance documentation

Accelerating Advanced Therapy Treatments with the FDA’s RMAT Designation

An introduction to the FDA’s RMAT designation with Dr Julie Allickson, Director, Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine

Innovations for Scalable Manufacturing of Allogeneic Cell Therapy...

Allogeneic cell therapies are poised to become a new frontier for therapeutic medicines. However, reliable and scalable...

[WEBINAR] Is a non-viral gene editing approach the answer to...

Exploring the next generation of non-viral gene-editing technologies

Automation Special Interest Group: Report 2019

The 2019 Automation SIG identified some of the biggest opportunities to improve manufacturing efficiency and accuracy. This...

[WEBINAR] Overcoming the shortages in cell and gene therapy...

A panel of advanced therapy manufacturing experts explore strategies to overcome the global manufacturing shortage

[Blog] Measuring success from conferences is getting harder, here&...

A case study from the Business of Regenerative Medicine 2019 

60 seconds with...

Dr Angela Colbert, Knight Vice President Education at the Frost Science Museum, Miami

Nominate now

Tell us who your top cell and gene therapy biotechs to watch in 2020 are

Functionality of non-virally transfected T cells

A summary of Dr Shirley O'Dea's presentation and data from Phacilitate Leaders Europe

60 Seconds with...Frances Pang, Orchard Therapeutics

Frances Pang, VP Global Market Access at Orchard Therapeutics on evolving access and reimbursement structures, HTA engagement and commercial success

60 Seconds with...Pilar Pinilla-Dominguez, NICE

Pilar Pinilla-Dominguez, Senior Scientific Adviser at NICE on reimbursement models for advanced therapies

Advanced Therapies Opportunities in Europe

An overview of clinical, investment and market approval activity in Europe

Translating Scientific and Technology Innovations from Academic...

An unmissable interview with Dr Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania

1
2
3
4
5
6
7
next
last

Cell and Gene Therapy